Attana to present at the CLINAM, Clinical Nanomedicin, Summit in Basel September 2 - 5, 2018
The CLINAM Summit "11th European and Global Summit for Clinical Nanomedicine, Targeted Delivery and Precision Medicine – The Building Blocks to Personalized Medicine", is a global event that brings together stakeholders in nanomedicine. Based on recent groundbreaking achievements, the summit will explore the pathways to personalized medicine in diagnosis, therapy and development of materials and tools for the discipline. Attana will attend the conference as a speaker. The presentation, “Towards Prediction of In Vivo Behavior of Nanoparticles: New Methods for Evaluation and Screening of Nanoparticles for Therapeutic Applications” will be given by Dr. Maria Gianneli, Applications specialist and Attana´s expert on nanoparticles assays. www.clinam.org
During the summit Dr. Gianneli will present how the Attana technology has been applied and can be used in nanomedical development. Dr. Gianneli will focus on results obtained together with UCD in the NanoClassifier project. These results have been recently published in two scientific publications. This is Attana´s first market efforts in the nanomedicine area driven by the knowledge and market understanding obtained and developed in the two EU-funded projects NanoClassifier and NanoMile. In those projects Attana´s cell-based technology has been used for characterization of interactions between nanoparticles and cells or proteins. The gained information can be used to improve the understanding of nanoparticles behaviour in the environment and the biological effect, in particular for nanoparticles use as therapeutics or in diagnostics.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com
tel: + 46 8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact sales@attana.com.
Tags:
